Download
1 / 44
470 likes | 1.91k Vues
Previous history of autoimmune thyroid disease. Positive TPOAb. If thyrotoxic profile ... disease (TRAbs) If hypothyroid and symptomatic start on T4 (for approx 6 months) Thyroid ...
E N D
Slide 2:What Controls Our Workload? Screening Expectations of the Patient Requesting Strategies Treatment of Sub-Clinical Disease Treatment/follow-up regimens Unnecessary tests
Managing Thyroid Function Tests
Guidelines ! Managing Thyroid Function Tests 1998 2000 2002 2003 None tend to meet requirement of patients , physicians and laboratories UK Guidelines For The Use of Thyroid Function Tests Published on Web July 2006 Draft Consultation Document October 2005 33 responses Group comprised of representatives from Association for Clinical Biochemistry British Thyroid Association British Thyroid Foundation Chaired by Dr Graham Beastall Graham H Beastall BSc, PhD, FRCPath Secretary, Guidelines Development Group Consultant Clinical Scientist, Glasgow Geoffrey J Beckett BSc, PhD, FRCPath Association for Clinical Biochemistry Reader in Clinical Biochemistry, Edinburgh Jayne Franklyn MD, PhD, FRCP, FMedSci British Thyroid Association Professor of Medicine, Birmingham William D Fraser MD, MRCP, FRCPath Association for Clinical Biochemistry Professor of Clinical Biochemistry, Liverpool Janis Hickey British Thyroid Foundation Founder and Director Rhys John BSc, PhD, FRCPath Association for Clinical Biochemistry Consultant Clinical Scientist, Cardiff Pat Kendall-Taylor MD DCH FRCP British Thyroid Association Professor of Endocrinology, Newcastle Upon Tyne Betty Nevens British Thyroid Foundation Office Manager Mark Vanderpump MD, FRCP British Thyroid Association Consultant Physician, London Introduction Indications for thyroid function testing Hypothyroidism Hyperthyroidism Thyroid function in pregnancy Thyroid function testing in thyroid cancer Laboratory aspects of thyroid function testing UK Thyroid Guidelines - Chapters Should Laboratories Make Local Bias Adjustments to the TSH Action Limits? At several points in the text numerical results are represented (eg TSH > 10 mU/L) Whickham Bias unknown Functional Sensitivity likely to be in the order of 1-2 mU/L In-house RIA Calibrated to 1st IRP Colorado study London Diagnostics Nichols Institute Diagnostics Bias ? Rotterdam Study Brahms Lumitest Bias? Evidence Base Introduction Chapter At several points in the text numerical results are represented (eg TSH > 10 mU/L) These should be regarded as typical target figures rather than as absolute cut-offs The historical nature of some of the evidence base together with uncertainty of the bias of the assays used in older studies means that absolute cut-offs cannot be presented. Laboratories should use EQA and other data to determine if biasrelated cut-offs are appropriate for the methods they use. In most cases it is unlikely that laboratories will have sufficient data to achieve an accurate adjustment of the TSH cut-offs quoted in these guidelines. Screening in the healthy population is not warranted Screening Women at the menopause or if visiting a GP with non-specific symptoms, may be justified to have TFTs in view of the high prevalence of thyroid failure Hospitalised Patients Routine testing of thyroid function in patients admitted acutely to hospital is not warranted unless there are specific clinical indications exist. Which Thyroid Function Test? TSH alone as first line test ? Cascade to T4 / T3 if TSH abnormal TSH with Free T4 as first-line tests ? Cascade with T3 if TSH is low Digivote response from RCPath meeting in London TSH alone TSH and T4 (free or total) TSH, T4, T3 (free or total) TSH and T3 (free or total) T4 (free or total) alone Given no financial or other restrictions:- What would be your preferred TFT strategy? 72% 9 % 17% 2% 0% TSH and FT4 needed in:- Symptomatic Patients being tested for the first time Screening/monitoring pregnancy Pituitary axis is not intact or unstable Hyperthyroidism- Early months of anti-thyroid therapy Hypothyroidism -Optimising T4 therapy (new patients) Central hypothyroidism TSHoma End organ resistance UK Guidelines TSH alone Stable - on T4 Follow-up of at risk patients AF Dyslipidaemia Osteoporosis Subfertility Cascade to FT4/FT3 if TSH is abnormal Surveillance of At Risk Patients Using TSH Diabetes Type 1 Annual TFT check Type 2 Check TFT at diagnosis Routine annual testing is not recommended Down and Turners syndrome Annual check Amiodarone Check before treatment Monitor every 6 months; continue to 12 months after cessation Lithium Check before treatment Monitor every 6 12 months Post neck irradiation Annual check Radioiodine / Thyroid surgery Needs T4 not TSH for first 6-12 months 4-8 weeks post treatment 3 monthly for first year Annually thereafter with TSH It is the responsibility of the requesting physician to provide clinical information to guide the laboratory in the selection of the most appropriate TFT. If labs are unable to identify those specimens that require TSH and FT4, it may be prudent to measure TSH+FT4 rather than embark on first-line TSH. UK Guidelines Sub-clinical Hypothyroidism High TSH with normal FT4 Exclude transient and drug causes of elevated TSH, exclude recovery from NTI. Repeat to confirm at 3-6 months No Change in recommendations:- TSH > 10 mU/L Treat with T4 Treating Sub-Clinical HypothyroidismSlide 23:Treating Sub-Clinical Hypothyroidism?
Many patients with raised TSH that is < 10 mU/L will normalise TSH with time
Spontaneous Normalization of Thyrotropin Concentrations in Patients with Subclinical Hypothyroidism Juan J. Dez, Pedro Iglesias and Kenneth D. Burman 40/107 patients normalised TSH on follow-up 12 (18) 72 months TSH raised but < 10 mU/L There is no clear evidence to support the benefit of routine early treatment with T4 in non-pregnant patients. A high percentage (~ 10%) of patients treated with T4 will have a TSH < 0.1 mU/L (Harmful? to bone and heart) Treating Sub-Clinical Hypothyroidism? Physicians may wish to consider the suitability of a therapeutic trial of T4 on an individual patient basis eg goitre or seeking pregnancy The primary target of T4 replacement therapy is:- Make the patient feel well Achieve a TSH that is within the reference range (FT4 may have to be slightly above reference range to achieve this) Thyroxine Replacement Therapy There is no compelling evidence or need to lower the upper reference limit or treatment target to 2.5 mU/L in non-pregnant patients NHANES study (USA) 17,353 subjects 13,344 Reference population TPO Ab negative Reference Range was 0.45 4.2 Denmark 1512 subjects Reference population TPO Ab negative Reference Range 0.58 4.1 Studies Using Ultrasound Exclusion with TPOAb SHIP study Germany 1488 subjects (previous iodine deficiency) Ref range 0.25 2.12 Germany 453 blood donors Ref Range 0.4 3.77 Denmark 3174 participants Ref Range 0.4 3.6 Published Reference Ranges Monitoring T4 Therapy TSH and T4 is required for initial optimisation of T4 therapy At least annual follow-up with TSH alone If T4 dose is changed allow 2-3 months before checking TFTs Be alert (inform patient) to concomitant drug treatment Impaired Absorption of T4 PPIs / H2 antagonists Calcium carbonate Soy protein Aluminium hydroxide Ferrous sulphate Cholestyramine Cholestapol Sucralfate Increased metabolism Phenytoin Carbamazepine Barbiturates Rifampicin Altered TBG Oestrogens, Tamoxifen Heroin, Methadone Androgens, Anabolic steroids Glucocorticoids Sub-Clinical Hyperthyroidism Low TSH normal T4 and T3 Exclude NTI/drugs Repeat 1-2 months later Persistent sub-clinical hyperthyroidism should prompt a specialist referral. If treatment is not undertaken measure TSH every 6-12 months (with FT4 and FT3 if TSH is low) Pregnancy Use both TSH and FreeT4 (Free T3 if TSH is low) to asses thyroid status and monitor T4 therapy Use Trimester-Related Ref Ranges For All Tests 0.1 5.0 TSH mU/L Screening for Thyroid Disease in Pregnancy Type 1 diabetes Previous history of thyroid disease Current thyroid disease Family history of thyroid disease Goitre Features of hypothyroidism Use TSH and Free T4 Consider TPOAb as a predictor of post partum thyroiditis and foetal impairment Hypothyroidism and Pregnancy For patients with established hypothyroidism check TFTs Before conception (if possible) At diagnosis of pregnancy At antenatal booking At least one in each trimester and 2-4 weeks postpartum Newly diagnosed patients Should be checked ever 4-6 weeks until stabilised T4 Therapy and Pregnancy First trimester Adjust T4 dose such that Free T4 is at upper half of non-pregnant ref range and TSH is low normal 0.4 2.0 mU/L Ideally monitor against trimester related reference ranges Patients who become pregnant usually need an extra 25-50 micrograms of T4. Reduce dose approx 4 weeks after delivery TRAbs and Pregnancy Patients with current or previous hyperthyroidism may benefit from a TRAbs at antenatal booking. If negative need not be measured again. High titre can predict chance of intrauterine thyrotoxicosis Post-partum Thyroiditis Occurs in 5% of population within 2-6 months of delivery or miscarriage. (non-specific symptoms tiredness, anxiety, depression) Post-partum patients should have TFTs at 6-8 weeks if they have:- Goitre Previous history of post-partum thyroiditis Previous history of autoimmune thyroid disease Positive TPOAb If thyrotoxic profile - differentiate from Graves disease (TRAbs) If hypothyroid and symptomatic start on T4 (for approx 6 months) Thyroid Cancer Thyroglobulin and TgAb TgAb are useful as :- A prognostic indicator To validate the reliability of a Tg measurement TgAb should be measured at diagnosis and simultaneously with Tg for follow-up Thyroid Cancer Thyroglobulin and TgAb Identify possible assay interference by RIA/IMA discordance TgAb positive samples Recovery alone is not recommended Discordant RIA / IMA Tg results at Edinburgh Royal Infirmary over a 17 month period. 14% of total results RIA/IMA concordance in Tg Ab Negative Samples IMA Data from Edinburgh Royal Infirmary RIA/IMA concordance in TgAb positive samples Sanofi IRMA Radioimmunoassay Data from Edinburgh Royal Infirmary There is a UK NEQAS scheme for thyroglobulin. Data from scheme illustrates the poor performance of Tg assays How Should We Inform GPs ? Guideline Group Plan to Produce a Version for GPs But Perhaps Labs should give GPs a brief version of the relevant points that are applicable to local practice. eg When to request TSH and TSH + FT4 Screening in menopause When to repeat tests in SC thyroid disease When to refer SC hyperthyroidism Target for T4 therapy Drugs and T4 therapy Pregnancy issues After Consultation with the Local Endocrinologists And Obstetricians!
